{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:19:37Z","timestamp":1783487977963,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001360"],"award-info":[{"award-number":["82001360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371999"],"award-info":[{"award-number":["82371999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071963"],"award-info":[{"award-number":["82071963"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["24BJZ14"],"award-info":[{"award-number":["24BJZ14"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Technology Innovation 2030","award":["2021ZD0201802"],"award-info":[{"award-number":["2021ZD0201802"]}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242128"],"award-info":[{"award-number":["7242128"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-NHLHCRF-YXHZ-ZD-01"],"award-info":[{"award-number":["2025-NHLHCRF-YXHZ-ZD-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02069-6","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:26:19Z","timestamp":1778559979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative performance of semi-quantitative methods for amyloid deposition in preclinical autosomal dominant Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"7","key":"2069_CR1","doi-asserted-by":"publisher","first-page":"e70347","DOI":"10.1002\/alz.70347","volume":"21","author":"A McCullough","year":"2025","unstructured":"McCullough A, Chen CD, Gordon BA, Joseph-Mathurin N, Jack CR Jr., Koeppe R, et al. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial. Alzheimers Dement. 2025;21(7):e70347.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2069_CR2","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338.","journal-title":"Alzheimers Dement"},{"issue":"Suppl 1","key":"2069_CR3","doi-asserted-by":"publisher","first-page":"s13","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. J Nucl Med. 2022;63(Suppl 1):s13\u20139.","journal-title":"J Nucl Med"},{"issue":"10","key":"2069_CR4","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2069_CR5","first-page":"175","volume":"67","author":"K Chiotis","year":"2026","unstructured":"Chiotis K, Wang Y, La Joie R, Rabinovici GD. The Role of Amyloid-\u03b2 and Tau PET in the New Era of Alzheimer Disease Therapies. J Nucl Med. 2026;67(2):175\u201385.","journal-title":"J Nucl Med"},{"issue":"6","key":"2069_CR6","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/alz.12886","volume":"19","author":"LE Collij","year":"2023","unstructured":"Collij LE, Salvad\u00f3 G, de Wilde A, Altomare D, Shekari M, Gispert JD, et al. Quantification of [(18) F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project. Alzheimers Dement. 2023;19(6):2397\u2013407.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2069_CR7","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Ro\u00e9-Vellv\u00e9 N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024;20(12):9037\u201348.","journal-title":"Alzheimers Dement"},{"issue":"23","key":"2069_CR8","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174\u201384.","journal-title":"J Neurosci"},{"issue":"12","key":"2069_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archneurol.2009.285","volume":"66","author":"VL Villemagne","year":"2009","unstructured":"Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66(12):1537\u201344.","journal-title":"Arch Neurol"},{"issue":"6","key":"2069_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","volume":"14","author":"AD Cohen","year":"2018","unstructured":"Cohen AD, McDade E, Christian B, Price J, Mathis C, Klunk W, et al. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer\u2019s disease from late-onset amyloid deposition. Alzheimers Dement. 2018;14(6):743\u201350.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2069_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14(10):1281\u201392.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2069_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-019-0468-1","volume":"11","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Lopera F, Sperling RA, Norton DJ, Guzman-Velez E, Baena A, et al. Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):17.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2069_CR13","doi-asserted-by":"publisher","first-page":"fcae159","DOI":"10.1093\/braincomms\/fcae159","volume":"6","author":"L Iaccarino","year":"2024","unstructured":"Iaccarino L, Llibre-Guerra JJ, McDade E, Edwards L, Gordon B, Benzinger T, et al. Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer\u2019s disease. Brain Commun. 2024;6(3):fcae159.","journal-title":"Brain Commun"},{"issue":"1","key":"2069_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13195-025-01690-1","volume":"17","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Wang Q, Liu L, Wang Q, Zhang X, Li C, et al. Investigating the A\u03b2 and tau pathology in autosomal dominant Alzheimer\u2019s disease: insights from hybrid PET\/MRI and network mapping. Alzheimers Res Ther. 2025;17(1):45.","journal-title":"Alzheimers Res Ther"},{"key":"2069_CR15","doi-asserted-by":"publisher","first-page":"758053","DOI":"10.3389\/fnagi.2021.758053","volume":"13","author":"L Fu","year":"2021","unstructured":"Fu L, Zhou Z, Liu L, Zhang J, Xie H, Zhang X, et al. Functional Abnormality Associated With Tau Deposition in Alzheimer\u2019s Disease - A Hybrid Positron Emission Tomography\/MRI Study. Front Aging Neurosci. 2021;13:758053.","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"2069_CR16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.apradiso.2011.04.010","volume":"69","author":"C Philippe","year":"2011","unstructured":"Philippe C, Haeusler D, Mitterhauser M, Ungersboeck J, Viernstein H, Dudczak R, et al. Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11\u00a0C]methylaminophenyl)-6-hydroxybenzothiazole ([11\u00a0C]PIB). Appl Radiat Isot. 2011;69(9):1212\u20137.","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"2069_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.media.2007.06.004","volume":"12","author":"BB Avants","year":"2008","unstructured":"Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12(1):26\u201341.","journal-title":"Med Image Anal"},{"issue":"1","key":"2069_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40658-023-00588-x","volume":"10","author":"M Shekari","year":"2023","unstructured":"Shekari M, Verwer EE, Yaqub M, Daamen M, Buckley C, Frisoni GB, et al. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan. EJNMMI Phys. 2023;10(1):68.","journal-title":"EJNMMI Phys"},{"issue":"11","key":"2069_CR19","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1002\/alz.14317","volume":"20","author":"VJ Lowe","year":"2024","unstructured":"Lowe VJ, Mester CT, Lundt ES, Lee J, Ghatamaneni S, Algeciras-Schimnich A, et al. Amyloid PET detects the deposition of brain A\u03b2 earlier than CSF fluid biomarkers. Alzheimers Dement. 2024;20(11):8097\u2013112.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2069_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55(10):1623\u20138.","journal-title":"J Nucl Med"},{"issue":"11","key":"2069_CR21","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","volume":"50","author":"A Jovalekic","year":"2023","unstructured":"Jovalekic A, Ro\u00e9-Vellv\u00e9 N, Koglin N, Quintana ML, Nelson A, Diemling M, et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging. 2023;50(11):3276\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2069_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u2013e151.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2069_CR23","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amyloid PET. Brain Behav. 2022;12(3):e2499.","journal-title":"Brain Behav"},{"issue":"3","key":"2069_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 2018;17(3):241\u201350.","journal-title":"Lancet Neurol"},{"issue":"47","key":"2069_CR25","doi-asserted-by":"publisher","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","volume":"110","author":"TL Benzinger","year":"2013","unstructured":"Benzinger TL, Blazey T, Jack CR Jr., Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2069_CR26","doi-asserted-by":"publisher","first-page":"732159","DOI":"10.3389\/fnagi.2021.732159","volume":"13","author":"Q Qin","year":"2021","unstructured":"Qin Q, Fu L, Wang R, Lyu J, Ma H, Zhan M, et al. Prominent Striatum Amyloid Retention in Early-Onset Familial Alzheimer\u2019s Disease With PSEN1 Mutations: A Pilot PET\/MR Study. Front Aging Neurosci. 2021;13:732159.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"2069_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr\u00e9 K, Mercken M, et al. Alzheimer\u2019s-Causing Mutations Shift A\u03b2 Length by Destabilizing \u03b3-Secretase-A\u03b2n Interactions. Cell. 2017;170(3):443\u2013e5614.","journal-title":"Cell"},{"issue":"5","key":"2069_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1039\/C2MB25457C","volume":"9","author":"SH Chong","year":"2013","unstructured":"Chong SH, Yim J, Ham S. Structural heterogeneity in familial Alzheimer\u2019s disease mutants of amyloid-beta peptides. Mol Biosyst. 2013;9(5):997\u20131003.","journal-title":"Mol Biosyst"},{"issue":"3","key":"2069_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/13506129.2011.580399","volume":"18","author":"M Inayathullah","year":"2011","unstructured":"Inayathullah M, Teplow DB. Structural dynamics of the \u2206E22 (Osaka) familial Alzheimer\u2019s disease-linked amyloid \u03b2-protein. Amyloid. 2011;18(3):98\u2013107.","journal-title":"Amyloid"},{"issue":"4","key":"2069_CR30","doi-asserted-by":"publisher","first-page":"e70141","DOI":"10.1002\/alz.70141","volume":"21","author":"M McLachlan","year":"2025","unstructured":"McLachlan M, Bettcher B, McVea A, DiFilippo A, Zammit M, LeMerise L, et al. The striatum is an early, accurate indicator of amyloid burden using [(11)C]PiB in Down syndrome: Comparison of two radiotracers. Alzheimers Dement. 2025;21(4):e70141.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2069_CR31","first-page":"e12020","volume":"12","author":"MD Zammit","year":"2020","unstructured":"Zammit MD, Laymon CM, Betthauser TJ, Cody KA, Tudorascu DL, Minhas DS, et al. Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimers Dement (Amst). 2020;12(1):e12020.","journal-title":"Alzheimers Dement (Amst)"},{"key":"2069_CR32","doi-asserted-by":"publisher","first-page":"117728","DOI":"10.1016\/j.neuroimage.2021.117728","volume":"228","author":"MD Zammit","year":"2021","unstructured":"Zammit MD, Tudorascu DL, Laymon CM, Hartley SL, Zaman SH, Ances BM, et al. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer\u2019s disease progression in Down syndrome. NeuroImage. 2021;228:117728.","journal-title":"NeuroImage"},{"issue":"8","key":"2069_CR33","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2069_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"2069_CR35","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, V\u00e1llez Garc\u00eda D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20(8):5102\u201313.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2069_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2069_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):22.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2069_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.","journal-title":"Alzheimers Res Ther"},{"key":"2069_CR39","doi-asserted-by":"publisher","first-page":"103765","DOI":"10.1016\/j.nicl.2025.103765","volume":"46","author":"L Iaccarino","year":"2025","unstructured":"Iaccarino L, Burnham SC, Tunali I, Wang J, Navitsky M, Arora AK, et al. A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research. Neuroimage Clin. 2025;46:103765.","journal-title":"Neuroimage Clin"},{"issue":"2","key":"2069_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.12779\/dnd.2025.24.2.135","volume":"24","author":"S Park","year":"2025","unstructured":"Park S, Kim K, Yoon S, Kim S, Ahn J, Lim KY, et al. Establishing Regional A\u03b2 Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain Amylo(\u00ae). Dement Neurocogn Disord. 2025;24(2):135\u201346.","journal-title":"Dement Neurocogn Disord"},{"issue":"1","key":"2069_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"2069_CR42","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"2069_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00401-025-02890-7","volume":"149","author":"CD Chen","year":"2025","unstructured":"Chen CD, Franklin EE, Li Y, Joseph-Mathurin N, Burns AL, Hobbs DA, et al. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta Neuropathol. 2025;149(1):57.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"2069_CR44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, et al. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol. 2025;24(11):931\u201344.","journal-title":"Lancet Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02069-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:02:27Z","timestamp":1783486947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02069-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02069-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the principles of the Declaration of Helsinki. All participants provided informed written consent to participate in the study. The study was approved by the institutional review board of the China-Japan Friendship Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}